Welcome to our dedicated page for Endonovo Therape news (Ticker: ENDV), a resource for investors and traders seeking the latest updates and insights on Endonovo Therape stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Endonovo Therape's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Endonovo Therape's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Endonovo Therapeutics, Inc. (OTCQB: ENDV) is advancing its clinical development for treating Traumatic Brain Injury (TBI) with its SofPulse® technology. The company is collaborating with prominent researchers and institutions to evaluate SofPulse®'s effectiveness in alleviating TBI symptoms, including headaches and cognitive impairment. The response from the scientific community has been overwhelmingly positive, indicating significant interest in the technology's potential. The global market for CNS therapeutics is projected to grow from $116.2 billion in 2020 to $214.8 billion by 2028, with the TBI market alone expected to reach $4.5 billion by 2026. Endonovo aims to achieve FDA clearance and reimbursement for SofPulse® treatments, positioning itself for substantial growth in the expanding CNS market.
Endonovo Therapeutics, Inc. (ENDV) announces a partnership with former NFL player David Irving as a brand ambassador for its non-opioid pain relief device, SofPulse®. Irving will share his experiences using the device, which employs Pulsed Electro Magnetic Field (PEMF) therapy showing positive effects on chronic pain and joint injuries. Irving, who retired due to health issues caused by concussions, emphasizes the need for non-pharmaceutical solutions for pain management. The partnership aims to advance awareness of SofPulse® among athletes and patients. Endonovo plans to expand research on PEMF therapy, aiming for FDA clearance for treating traumatic brain injury (TBI), post-concussion syndrome (PCS), and other CNS disorders, highlighting the device's potential in the $40.25 billion pain management market.
FAQ
What is the current stock price of Endonovo Therape (ENDV)?
What is the market cap of Endonovo Therape (ENDV)?
